C-terminal truncated HBx reduces doxorubicin cytotoxicity via ABCB1 upregulation in Huh-7 hepatocellular carcinoma cells |
Jegal, Myeong-Eun
(Department of Molecular Biology, College of Natural Science, Pusan National University)
Jung, Seung-Youn (Department of Molecular Biology, College of Natural Science, Pusan National University) Han, Yu-Seon (Department of Molecular Biology, College of Natural Science, Pusan National University) Kim, Yung-Jin (Department of Molecular Biology, College of Natural Science, Pusan National University) |
1 | Wang J, Alexanian A, Ying R et al (2012) Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol 32, 712-720 DOI |
2 | Sze KM, Chu GK, Lee JM and Ng IO (2013) C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. Hepatology 57, 131-139 DOI |
3 | Zhang H, Shan CL, Li N et al (2008) Identification of a natural mutant of HBV X protein truncated 27 amino acids at the COOH terminal and its effect on liver cell proliferation. Acta Pharmacol Sin 29, 473-480 DOI |
4 | Zhang X, Ye LH and Zhang XD (2010) A mutant of hepatitis B virus X protein (HBx Delta 127) enhances hepatoma cell migration via osteopontin involving 5-lipoxygenase. Acta Pharmacol Sin 31, 593-600 DOI |
5 | Ma NF, Lau SH, Hu L et al (2008) COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis. Clin Cancer Res 14, 5061-5068 DOI |
6 | Quetier I, Brezillon N, Revaud J et al (2015) C-terminaltruncated hepatitis B virus X protein enhances the development of diethylnitrosamine-induced hepatocellular carcinogenesis. J Gen Virol 96, 614-625 DOI |
7 | Ng KY, Chai S, Tong M et al (2016) C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties. Oncotarget 7, 24005-24017 DOI |
8 | Kachalaki S, Ebrahimi M, Mohamed Khosroshahi L, Mohammadinejad S and Baradaran B (2016) Cancer chemoresistance; biochemical and molecular aspects: a brief overview. Eur J Pharm Sci 89, 20-30 DOI |
9 | Wu Q, Yang Z, Nie Y, Shi Y and Fan D (2014) Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett 347, 159-166 DOI |
10 | Kathawala RJ, Gupta P, Ashby CR Jr and Chen ZS (2015) The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist Updat 18, 1-17 DOI |
11 | Januchowski R, Wojtowicz K, Andrzejewska M and Zabel M (2014) Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines. Biomed Pharmacother 68, 111-117 DOI |
12 | Dean M, Fojo T and Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284 DOI |
13 | Saad M, Garbuzenko OB and Minko T (2008) Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) 3, 761-776 DOI |
14 | Nourbakhsh M, Jaafari MR, Lage H et al (2015) Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iran J Basic Med Sci 18, 385-392 |
15 | Yeo W, Lam KC, Zee B et al (2004) Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15, 1661-1666 DOI |
16 | Jung SY and Kim YJ (2013) C-terminal region of HBx is crucial for mitochondrial DNA damage. Cancer Lett 331, 76-83 DOI |
17 | Broxterman HJ, Gotink KJ and Verheul HM (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12, 114-126 DOI |
18 | Llovet JM (2005) Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40, 225-235 DOI |
19 | Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57, 727-741 DOI |
20 | Nitiss KC and Nitiss JL (2014) Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage. Clin Cancer Res 20, 4737-4739 DOI |
21 | Ng SA and Lee C (2011) Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol 46, 974-990 DOI |
22 | Liu N, Chen T, Wang X, Yang D, Xue B and Zhu H (2015) Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells. FEBS Lett 589, 897-903 DOI |
23 | Arzumanyan A, Reis HM and Feitelson MA (2013) Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 13, 123-135 DOI |
24 | Martin-Vilchez S, Lara-Pezzi E, Trapero-Marugan M, Moreno-Otero R and Sanz-Cameno P (2011) The molecular and pathophysiological implications of hepatitis B X antigen in chronic hepatitis B virus infection. Rev Med Virol 21, 315-329 DOI |
25 | Ali A, Abdel-Hafiz H, Suhail M et al (2014) Hepatitis B virus, HBx mutants and their role in hepatocellular carcinoma. World J Gastroenterol 20, 10238-10248 DOI |
26 | Kim CM, Koike K, Saito I, Miyamura T and Jay G (1991) HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351, 317-320 DOI |
27 | Fan W, Shi B, Wei H, Du G and Song S (2011) Comparison of hepatitis B X gene mutation between patients with hepatocellular carcinoma and patients with chronic hepatitis B. Virus Genes 42, 162-170 DOI |